Korol Andrii R, Zadorozhnyy Oleg S, Naumenko Volodymyr O, Kustryn Taras B, Pasyechnikova Nataliya V
The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odessa, Ukraine.
Clin Ophthalmol. 2016 Nov 4;10:2223-2229. doi: 10.2147/OPTH.S117791. eCollection 2016.
To determine the efficacy of intravitreal aflibercept injections for the treatment of patients with choroidal neovascularization (CNV) associated with pathologic myopia.
In this uncontrolled, prospective cohort study, 31 eyes of 30 consecutive patients affected by CNV associated with pathologic myopia were treated with intravitreal aflibercept (2 mg) as needed following two initial monthly doses and observed over a 12-month follow-up period. The primary endpoint was change in best-corrected visual acuity (BCVA) at month 12, while central retinal thickness (CRT) on optical coherence tomography (OCT), neovascularization activity on fluorescein angiography, the number of aflibercept injections administered, and safety were examined as secondary endpoints.
Patients received a mean of 2.6 intravitreal aflibercept injections over the 12-month study period. Compared with baseline, BCVA improved significantly at all time points (<0.05). Mean (standard deviation [SD]) decimal BCVA was 0.2 (0.1) at baseline and 0.35 (0.16) at month 12. The greatest improvement in BCVA was seen within the first 2 months (=0.01). Mean (SD) CRT on OCT decreased from 285 (62) µm at baseline to 227 (42) µm (=0.01) at month 12. There was a continuous decrease in mean CRT on OCT over time. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mmHg during any study visit.
The 12-month results of intravitreal aflibercept for myopic CNV using an as-needed regimen were positive, showing benefits in visual and anatomic outcomes and an acceptable tolerability profile.
确定玻璃体内注射阿柏西普治疗病理性近视相关脉络膜新生血管（CNV）患者的疗效。
在这项非对照前瞻性队列研究中，30例连续患有病理性近视相关CNV的患者的31只眼，在最初每月两次给药后，根据需要接受玻璃体内注射阿柏西普（2mg）治疗，并在12个月的随访期内进行观察。主要终点是第12个月时最佳矫正视力（BCVA）的变化，而光学相干断层扫描（OCT）上的中心视网膜厚度（CRT）、荧光素血管造影上的新生血管活性、阿柏西普注射次数以及安全性作为次要终点进行检查。
在12个月的研究期间，患者平均接受2.6次玻璃体内阿柏西普注射。与基线相比，所有时间点的BCVA均有显著改善（<0.05）。平均（标准差[SD]）小数视力在基线时为0.2（0.1），在第12个月时为0.35（0.16）。BCVA在最初2个月内改善最大（=0.01）。OCT上的平均（SD）CRT从基线时的285（62）μm降至第12个月时的227（42）μm（=0.01）。随着时间的推移，OCT上的平均CRT持续下降。未观察到眼内炎、葡萄膜炎、中风或视网膜脱离病例。在任何研究访视期间，没有患者的眼压>20 mmHg。
采用按需给药方案的玻璃体内注射阿柏西普治疗近视性CNV的12个月结果是积极的，在视力和解剖学结果方面显示出益处，且耐受性良好。
